The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Click here to find out why I rate VERV ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

The Boston-based company said its gene-editing treatment for people with high cholesterol was well-tolerated with no serious ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

In recent years, mRNA technology enabled the rapid development of vaccines to fight COVID-19, saving millions of lives.

Researchers at UW are pioneering long-acting injectable HIV therapies that have the potential to simplify and expand ...

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.